NEW YORK (GenomeWeb) – Trovagene announced Thursday after the close of the market that its third quarter net loss widened as its revenues inched up to $57,000 from $44,000 in Q3 2014.

The firm posted a net loss of $5.4 million, or $.28 per share, for the three months ended Sept. 30, as compared to a net loss of $4.4 million, or $.25 per share, in Q3 2014.

The increased loss is primarily due to an increase in operating expenses as compared to a year ago, the firm said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.